Pyridyl amide T-type calcium channel antagonists
View Patent ↗The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
1. A compound of the formula:
wherein:
R 1a is selected from the group consisting of:
(1) halogen,
(2) phenyl, which is unsubstituted or substituted with halogen, hydroxyl, C 1-6 alkyl, —O—C 1-6 alkyl, C 3-6 cycloalkyl, or —NO 2 ,
(3) —O-phenyl, which is unsubstituted or substituted with halogen, hydroxyl, C 1-6 alkyl, —O—C 1-6 alkyl,
(4) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,
(5) C 3-6 cycloalkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl, and
(6) C 2-4 alkenyl, which is unsubstituted or substituted with C 3-6 cycloalkyl or phenyl;
R 5a is independently selected from the group consisting of:
(1) hydrogen,
(2) fluoro,
(3) chloro,
(4) bromo,
(5) hydroxyl,
(6) —CH 3 ,
(7) —CH 2 OH,
(8) —CH 2 CH 3 ,
(9) —CH 2 ═CH 2 ,
(10) —CH 2 CH 2 CH 3 ,
(11) -cyclopropyl,
(12) —OCH 3 ,
(13) —OCH 2 F,
(14) —OCH 2 -cyclopropyl,
(15) —OCH 2 -phenyl,
(16) —OCH 2 CH 3 ,
(17) —OCH 2 CF 3 ,
(18) —OCH 2 CH 2 CH 3 ,
(19) —OCH 2 (C═O)OCH 2 CH 3 ,
(20) —OCH 2 (C═O)NHCH 2 CH 3 ,
(21) —OSO 2 CH 3 , and
(22) —O(C═O)OCH 3 ;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 of the formula:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 wherein R 1a is phenyl which is unsubstituted or substituted with one or more halogen.
4. The compound of claim 1 wherein R 1a is C 1-6 alkyl.
5. The compound of claim 1 wherein R 1a is isopropyl or tert-butyl.
6. The compound of claim 1 wherein R 1a is isopropyl.
7. The compound of claim 1 wherein R 1a is cyclopropyl.
8. The compound of claim 1 wherein R 5a is —OCH 2 CF 3 .
9. A compound which is selected from the group consisting of:
N-[(1R)-1-(5-bromopyridin-2-yl)ethyl]-2-(4-isopropylphenyl)acetamide;
2-(1,1′-biphenyl-4-yl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]acetamide;
2-(1,1′-biphenyl-4-yl)-N-[(1R)-1-(5-hydroxypyridin-2-yl)ethyl]acetamide;
2-(1,1′-biphenyl-4-yl)-N-[(1R)-1-(5-propoxypyridin-2-yl)ethyl]acetamide;
2-(4-isopropylphenyl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]acetamide;
N-[(1R)-1-(5-hydroxypyridine-2-yl)ethyl]-2-(4-isopropylphenyl)acetamide;
2-(4-isopropylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide;
2-[4-(1-hydroxy-1-methylethyl)phenyl]-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide;
2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide;
2-[4-(2-hydroxy-1-methylethyl)phenyl]-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide;
2-(4-Cyclopropylphenyl)-N-((1R)-1-{5-[(2,2,2-trifluoroethyl)oxo]pyridin-2-yl}ethyl)acetamide;
2-(4-tert-butylphenyl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]-acetamide;
2-(4-tert-butylphenyl)-N-[(1R)-1-(5-chloropyridin-2-yl)ethyl]acetamide;
2-(4-tert-butylphenyl)-N-[(1R)-1-(5-fluoropyridin-2-yl)ethyl]acetamide;
2-(4-vinylphenyl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]acetamide;
2-(4-cyclopropylphenyl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]acetamide;
2-(4-tert-butylphenyl)-N-{(1R)-1-[5-(fluoromethoxy)pyridin-2-yl]ethyl}acetamide;
2-biphenyl-4-yl-N-{(1R)-1-[5-(hydroxymethyl)pyridin-2-yl]ethyl}acetamide;
6-{(1R)-1-[(2-biphenyl-4-ylacetyl)amino]ethyl}pyridin-3-yl methanesulfonate;
6-{(1R)-1-[(biphenyl-4-ylacetyl)amino]ethyl}pyridin-3-yl methyl carbonate;
2-(4-isopropylphenyl)-N-[(1R)-1-(5-propoxypyridin-2-yl)ethyl]acetamide;
2-(4-isopropylphenyl)-N-[(1R)-1-(5-fluoromethoxypyridin-2-yl)ethyl]acetamide;
ethyl {[6-((1R)-1-{[(4-isopropylphenyl)acetyl]amino }ethyl)pyridin-3-yl]oxy}acetate
N-{(1R)-1-[5-(benzyloxy)pyridin-2-yl]ethyl}-2-(4-bromophenyl)acetamide;
2-(4-isopropenylphenyl)-N-[(1R)-1-(5-methoxypyridin-2-yl)ethyl]acetamide;
N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}-2-[4-(trifluoromethyl)phenyl]acetamide;
2-[4-(1-hydroxycyclopropyl)phenyl]-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide;
2-phenyl-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide;
2-[4-(1-methylcyclopropyl)phenyl]-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide;
2,2-difluoro-2-[4-(1-hydroxy-1-methylethyl)phenyl]-N-[(1R)-1-(5-{[(1S)-1-methylpropyl]oxy}pyridin-2-yl)ethyl]acetamide;
or a pharmaceutically acceptable salt thereof.
10. A compound which is selected from the group consisting of:
2-(4-isopropylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide;
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 10 which is 2-(4-isopropylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide.
12. A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition which comprises an inert carrier and a compound of claim 9 or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition which comprises an inert carrier and a compound of claim 10 or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition which comprises an inert carrier and a compound of claim 11 or a pharmaceutically acceptable salt thereof.